RxDoctor Payments Data

Michael Molinaro, MD

Internal Medicine · Glen Ridge, NJNPI 1144234634

Payments from drug & device makers

$646in general payments, 2019–2025

Across 16 payments — averaging $40.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teleflex LLC$283
  • AstraZeneca$133
  • GSK$98
  • Novo Nordisk$56
  • Lilly USA, LLC$38
  • Corcept Therapeutics$20
  • plus $18 from 1 others

What the payments were for

  • Food & beverage$646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$646 in reported general payments places this provider in the 60th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$258,098
Medicare patients
812
Services billed
4,285

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate114$109,053
EliquisApixaban81$80,784
OzempicSemaglutide70$75,473
MounjaroTirzepatide44$52,203
XareltoRivaroxaban31$34,999
FarxigaDapagliflozin Propanediol36$33,515
LipitorAtorvastatin Calcium17$25,217
JardianceEmpagliflozin22$24,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$19,819
Breo ElliptaFluticasone/Vilanterol42$17,258
Atorvastatin Calcium1,215$13,265
LivaloPitavastatin Calcium11$9,546
Rosuvastatin Calcium555$8,147
Lagevrio (Eua)Molnupiravir13$7,452
TradjentaLinagliptin15$7,230

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$56$75,47370 claims
Lilly USA, LLCMounjaro$38$52,20344 claims
GSKTrelegy Ellipta, Breo Ellipta$98$37,07756 claims
AstraZenecaFarxiga$133$33,51536 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Glen Ridge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →